Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Operations: 2020-2024

Historic Cash from Operations for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to -$122.9 million.

  • Prime Medicine's Cash from Operations fell 35.22% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.1 million, marking a year-over-year increase of 40.39%. This contributed to the annual value of -$122.9 million for FY2024, which is 25.72% up from last year.
  • Per Prime Medicine's latest filing, its Cash from Operations stood at -$122.9 million for FY2024, which was up 25.72% from -$165.4 million recorded in FY2023.
  • Prime Medicine's Cash from Operations' 5-year high stood at -$5.5 million during FY2020, with a 5-year trough of -$165.4 million in FY2023.
  • Over the past 3 years, Prime Medicine's median Cash from Operations value was -$131.8 million (recorded in 2022), while the average stood at -$140.0 million.
  • In the last 5 years, Prime Medicine's Cash from Operations slumped by 514.75% in 2021 and then climbed by 25.72% in 2024.
  • Yearly analysis of 5 years shows Prime Medicine's Cash from Operations stood at -$5.5 million in 2020, then tumbled by 514.75% to -$34.1 million in 2021, then slumped by 286.79% to -$131.8 million in 2022, then fell by 25.48% to -$165.4 million in 2023, then rose by 25.72% to -$122.9 million in 2024.